Persistent effects with tamoxifen in breast cancer prevention

    loading  Checking for direct PDF access through Ovid

Abstract

Long-term follow-up results of the IBIS-I* study, presented in three analyses at the 29th San Antonio Breast Cancer Symposium (SABCS) [San Antonio, Texas, US; December 2006], show that tamoxifen is effective in the prevention of breast cancer, including estrogen receptor (ER)-positive but not ER-negative disease, even up to 4 years after treatment discontinuation in women at increased risk for breast cancer. Additionally, adverse events associated with tamoxifen administration are reduced once treatment is discontinued. Despite these positive results it appears that breast cancer mammographic density, reduced during tamoxifen therapy, is increased 1 year after the discontinuation of tamoxifen.

Related Topics

    loading  Loading Related Articles